Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395258 | 0.82 | ALDH1A1 (0.54) | HDAC2CSNK2A1IMPDH2ALDH1A1HSD17B10 | |
| SCHEMBL2010826 | 0.81 | ESR1 (0.39) | HDAC2CSNK2A1IMPDH2LPLLIPG | |
| SCHEMBL7453950 | 0.79 | CSNK2A1 (0.40) | HDAC2CSNK2A1IMPDH2LPLLIPG | |
| Hydrochloric Acid SCHEMBL7453311 | 0.77 | CSNK2A1 (0.42) | HDAC2CSNK2A1IMPDH2LPLLIPG | |
| SCHEMBL15624627 | 0.76 | ALDH1A1 (0.42) | HDAC2CSNK2A1IMPDH2ALDH1A1HSD17B10 | |
| SCHEMBL19198893 | 0.76 | TDP1 (0.43) | HDAC2CSNK2A1IMPDH2LPLLIPG | |
| SCHEMBL6873485 | 0.74 | CSNK2A1 (0.44) | HDAC2CSNK2A1IMPDH2ALDH1A1HSD17B10 | |
| SCHEMBL7461363 | 0.72 | CSNK2A1 (0.36) | HDAC2CSNK2A1IMPDH2LPLLIPG | |
| SCHEMBL7459930 | 0.72 | HDAC2 (0.36) | HDAC2CSNK2A1IMPDH2LPLLIPG | |
| SCHEMBL7696358 | 0.71 | IMPDH2 (0.38) | CSNK2A1IMPDH2LPLLIPGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329741-B2 | HBV inhibitor and its use | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2025-06-17 | — | — | US | disclosed |
| US-20240139152-A1 | HBV INHIBITOR AND ITS USE | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| CN-117903110-A | HBV inhibitors and uses thereof | 西安新通药物研究股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11903924-B2 | HBV inhibitor and its use | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2024-02-20 | — | — | US | disclosed |
| CN-114901639-B | HBV inhibitors and uses thereof | 西安新通药物研究股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3919474-B1 | HBV INHIBITOR AND USE THEREOF | XIAN XINTONG PHARMACEUTICAL RES CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4245372-A2 | HBV INHIBITOR AND USE THEREOF | Xi'An Xintong Pharmaceutical Research Co., Ltd. (CN) | 2023-09-20 | — | — | EP | disclosed |
| CN-114901639-A | HBV inhibitor and application thereof | 西安新通药物研究股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220184035-A1 | HBV INHIBITOR AND ITS USE | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3919474-A1 | HBV INHIBITOR AND USE THEREOF | Xi'An Xintong Pharmaceutical Research Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-101437827-A | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD (JP) | 2009-05-20 | — | — | CN | disclosed |
| CN-101429200-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-1934116-A | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| US-3963717-A | ANTIINFLAMMATORY, ANALGESIC | SANDOZ, INC. (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329741-B2 | HBV inhibitor and its use | HAVCR2, HDGF, ZC3HAV1 | HDAC2 2033/4885CSNK2A1 4250/4885IMPDH2 513/4885 |
| US-11903924-B2 | HBV inhibitor and its use | HAVCR2, HDGF, ZC3HAV1 | HDAC2 2033/4885CSNK2A1 4250/4885IMPDH2 513/4885 |
| US-20240139152-A1 | HBV INHIBITOR AND ITS USE | HAVCR2, HDGF, ZC3HAV1 | HDAC2 2033/4885CSNK2A1 4250/4885IMPDH2 513/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | HDAC2 309/4885CSNK2A1 267/4885IMPDH2 3260/4885 |
| US-20220184035-A1 | HBV INHIBITOR AND ITS USE | HAVCR2, HDGF, ZC3HAV1 | HDAC2 2033/4885CSNK2A1 4250/4885IMPDH2 513/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | HDAC2 1100/4885CSNK2A1 915/4885IMPDH2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.